Jessica Hart
About Jessica Hart
Jessica Hart is a Safety Scientist specializing in Drug Safety and Pharmacovigilance at Canopy Growth Corporation in Montréal, Québec, Canada. She has over a decade of experience in the pharmaceutical industry, with a strong educational background in biomedical sciences and drug development.
Work at Canopy Growth
Jessica Hart has been employed at Canopy Growth Corporation since 2020, serving as a Safety Scientist in the Drug Safety and Pharmacovigilance department. Her role focuses on ensuring the safety of products and monitoring adverse effects associated with drug use. Based in Montréal, Québec, she has contributed to the company's commitment to maintaining high safety standards in the rapidly evolving cannabis industry.
Education and Expertise
Jessica Hart holds a DESS in Drug Development from Université de Montréal, which she completed from 2013 to 2016. Prior to this, she earned a B.Sc. in Biomedical Sciences from Université du Québec à Trois-Rivières between 2009 and 2012. Additionally, she studied at Cégep Édouard-Montpetit, where she obtained a D.E.C. in Sciences Santé from 2007 to 2009. This educational background provides her with a solid foundation in drug safety and pharmacovigilance.
Previous Work Experience
Before joining Canopy Growth, Jessica Hart worked at Mallinckrodt Pharmaceuticals as a Senior Pharmacovigilance Specialist from 2013 to 2020. Her earlier experience includes a position as a Drug Safety Specialist at Covidien for one year in 2012-2013. Additionally, she worked as a Junior Laboratory Technician at Archer Daniels Midland from 2010 to 2012. This diverse experience in the pharmaceutical and laboratory sectors has equipped her with extensive knowledge in drug safety.
Professional Background
Jessica Hart's professional journey spans various roles in the pharmaceutical industry, focusing on drug safety and pharmacovigilance. Her career began with a technical position at Archer Daniels Midland, followed by significant roles at Covidien and Mallinckrodt Pharmaceuticals. This progression reflects her commitment to advancing her expertise in safety science and her dedication to improving drug safety protocols.